Semaglutide vs. Tirzepatide: Understanding the Differences
Semaglutide and tirzepatide are prescription medications that may be considered by licensed healthcare providers as part of individualized treatment plans when clinically appropriate.
Although they are often discussed together, they are not the same medication. Both interact with hormone pathways involved in metabolic regulation, but they do so in different ways.
Understanding these differences can help you have a more informed conversation with your healthcare provider about your treatment options.
Compounded drugs are not FDA approved. This means that the FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
What Is Semaglutide?
Semaglutide belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists.
GLP-1 is a naturally occurring hormone released after eating. It participates in normal physiological processes related to digestion, insulin secretion, appetite regulation and blood glucose homeostasis.
Semaglutide interacts with the GLP-1 receptor, making it different from medications that target multiple incretin pathways. A licensed healthcare provider determines whether semaglutide may be appropriate after reviewing an individual's medical history, current medications and treatment goals. Compounded drugs are not FDA approved. This means that the FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
What Is Tirzepatide?
Tirzepatide is a medication that interacts with two hormone receptor pathways:
- Glucose-dependent insulinotropic polypeptide (GIP)
- Glucagon-like peptide-1 (GLP-1)
Because it activates both pathways, tirzepatide is commonly described as a dual incretin receptor agonist.
Like semaglutide, tirzepatide is intended to be prescribed only after evaluation by a licensed healthcare provider and used alongside healthy lifestyle habits rather than as a replacement for them. Compounded drugs are not FDA approved. This means that the FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
Understanding GIP and GLP-1
GIP and GLP-1 are incretin hormones naturally released by the digestive tract after eating.
These hormones help coordinate communication between the digestive system, pancreas, brain and other tissues involved in metabolic regulation. Researchers continue to study these pathways because they play important roles in normal physiological processes such as:
- Appetite regulation
- Digestion
- Insulin secretion
- Glucagon activity
- Blood glucose regulation
- Feelings of fullness
Although semaglutide and tirzepatide interact with these hormone pathways differently, both should be used only under the guidance of a licensed healthcare provider.
How Are They Similar?
Semaglutide and tirzepatide share several characteristics.
Both medications:
- Require a prescription
- Require evaluation by a licensed healthcare provider
- Are administered by subcutaneous injection
- Interact with incretin hormone pathways
- Are intended to complement healthy lifestyle habits
- Require ongoing follow-up during treatment
Neither medication should be viewed as a substitute for balanced nutrition, regular physical activity or individualized medical care.
What Makes Them Different?
The primary difference is the hormone receptors each medication targets.
Semaglutide interacts with the GLP-1 receptor.
Tirzepatide interacts with both the GLP-1 and GIP receptors.
While these hormone pathways are interconnected, they are distinct biological systems. Healthcare providers consider these differences alongside a patient's complete medical history, current health conditions and treatment goals when determining an appropriate treatment plan.
Comparison at a Glance
| Feature |
Semaglutide |
Tirzepatide |
| Medication class |
GLP-1 receptor agonist |
Dual GIP and GLP-1 receptor agonist |
| Prescription required |
Yes |
Yes |
| Administration |
Subcutaneous injection |
Subcutaneous injection |
| Hormone pathways |
GLP-1 |
GLP-1 and GIP |
| Requires provider evaluation |
Yes |
Yes |
| Ongoing follow-up |
Yes |
Yes |
Why Healthy Lifestyle Habits Still Matter
Medication is only one component of supporting long-term metabolic health.
Healthcare providers commonly encourage patients to focus on:
- Balanced nutrition
- Regular physical activity
- Adequate hydration
- Quality sleep
- Stress management
- Routine follow-up appointments
These healthy habits support overall wellness and complement individualized treatment plans.
How Healthcare Providers Choose a Treatment Plan
Treatment decisions are individualized.
A healthcare provider may consider:
- Medical history
- Current medications
- Existing health conditions
- Lifestyle factors
- Previous treatment experiences
- Personal health goals
- Questions or concerns about treatment
Because every person's health history is different, there is no single medication that is appropriate for everyone.
Questions to Ask Your Healthcare Provider
If you are considering semaglutide or tirzepatide, consider asking:
- How do these medications differ?
- Which option may be appropriate based on my health history?
- What lifestyle changes should accompany treatment?
- How will my progress be monitored?
- How often should I schedule follow-up visits?
- Are compounded medications available if clinically appropriate?
These conversations can help ensure treatment decisions are based on your individual needs rather than general information found online.
Compounded Semaglutide and Tirzepatide
Some patients may receive compounded semaglutide or compounded tirzepatide when a licensed healthcare provider determines that a compounded medication is clinically appropriate and legally available.
Compounded drugs are not FDA approved. This means that the FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
Compounded medications may differ in formulation, inactive ingredients, manufacturing processes and regulatory review. They should not be described as generic, identical or equivalent to an FDA-approved drug product.
Patients should discuss the potential risks, benefits and available treatment options with their healthcare provider.
Is Semaglutide or Tirzepatide Right for You?
Semaglutide and tirzepatide interact with different hormone pathways involved in metabolic regulation, but determining whether either medication is appropriate requires an individualized medical evaluation.
A licensed healthcare provider can review your medical history, discuss your health goals and determine whether semaglutide, tirzepatide or another treatment option may be appropriate for your individual needs.
Schedule a Consultation
TeleWellnessMD® connects patients with licensed healthcare providers who can review your medical history, discuss your health goals and determine whether semaglutide, tirzepatide or another treatment option may be appropriate.
Schedule a Consultation
This content is for educational and informational purposes only and should not be interpreted as medical advice. TeleWellnessMD® is a technology platform that connects patients with licensed healthcare providers. TeleWellnessMD® does not practice medicine, provide medical advice, or dispense medications. All therapies require evaluation and approval by a licensed healthcare provider. Results may vary. Compounded drugs are not FDA approved. This means that the FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
Sources
- Holst JJ. The physiology of glucagon-like peptide-1. Physiological Reviews.
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology.
- Chomiuk T, Niezgoda N, Mamcarz A, Śliż D. Physical Activity in Metabolic Syndrome. Frontiers in Physiology. 2024.
- Vincent GE, Jay SM, Sargent C, et al. Improving Cardiometabolic Health with Diet, Physical Activity and Breaking Up Sitting: What About Sleep? Frontiers in Physiology. 2017.